GLP-1 receptor antagonist approved by FDA for breakthrough therapy to treat children's hereditary hypoglycemia

A few days ago, Eiger BioPharmaceuticals announced that the US FDA has granted its potential "first-in-class" glucagon-like peptide-1 (GLP-1) receptor antagonist avexitide breakthrough therapy designation for the treatment of congenital hyperinsulinemia Congenital hyperinsulinism (congenital hyperinsulinism)
.

Avexitide is a peptide drug composed of 31 amino acids, which can selectively block the GLP-1 receptor and reduce the excessive secretion of insulin by the pancreas, thereby effectively treating the symptoms of fasting and postprandial hypoglycemia, and for the treatment of metabolic disorders.
Disease
.
Previously, the FDA has granted avexitide the orphan drug designation for the treatment of hyperinsulinemic hypoglycemia (including congenital hyperinsulinemia) and the designation of rare pediatric diseases

▲The molecular structure of Avexitide (picture source: Eiger's official website)

Congenital hyperinsulinemia is a life-threatening, progressive, inherited pediatric metabolic disorder that can cause irreversible brain damage in up to 50% of children
.
Due to the imbalance of insulin secretion by the pancreas, the patient presented with severe fasting and protein-induced hypoglycemia

(The original text has been deleted)

Reference materials:

[1] Eiger Announces FDA Breakthrough Therapy Designation for Avexitide for Treatment of Congenital Hyperinsulinism.